Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.
Price history
Loading NMRA daily closes…
Loading price history…
Pipeline assets
navacaprant
Phase 3 · TerminatedModality: small molecule (oral)
Target kappa opioid receptor (KOR)
Partnerships The Scripps Research Institute (TSRI; exclusive license via BlackThorn acquisition)
Indications
Major depressive disorder (MDD)(Phase 3)
Status note Kappa opioid receptor antagonist investigated in the KOASTAL pivotal Phase 3 program in moderate to severe MDD. Following Phase 3 KOASTAL program results in June 2026, the company is discontinuing development of navacaprant in MDD.
NMRA-511
Phase 1 · ActiveModality: small molecule (oral)
Target vasopressin 1a receptor (V1aR)
Partnerships The Scripps Research Institute (TSRI; exclusive license via BlackThorn acquisition)
Indications
Alzheimer's disease agitation(Phase 1)
Catalysts
— second half of 2026
— first quarter of 2027
Status note V1aR antagonist. Phase 1b results reported Q1 2026; MAD expansion cohort evaluating higher doses expected to report data H2 2026.
Partnerships Vanderbilt University (exclusive worldwide license)
Indications
Neuropsychiatric disorders(Stage not disclosed)
Status note M4 muscarinic receptor positive allosteric modulator; part of the M4 franchise with NMRA-898.
NMRA-215
Stage not disclosed · ActiveModality: small molecule (oral)
Target NLRP3
Indications
Obesity(Stage not disclosed)
Cardiovascular risk(Stage not disclosed)
Status note Oral NLRP3 inhibitor.
NMRA-GCase
Preclinical · Active
Target glucocerebrosidase (GCase)
Partnerships Amgen (exclusive worldwide license to compounds directed to glucocerebrosidase)
Indications
Neurodegenerative diseases(Preclinical)
Status note Preclinical program directed to glucocerebrosidase for neurodegenerative diseases.
NMRA-CK1δ
Stage not disclosed · ActiveModality: small molecule
Target casein kinase 1 delta (CK1δ)
Partnerships Amgen (exclusive worldwide license to compounds directed to casein kinase 1 delta)
Indications
Amyotrophic lateral sclerosis (ALS)(Stage not disclosed)
Status note Program directed to CK1 delta for TDP-43-driven pathology.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Institutional holders
Fund
Shares
Q/Q change
% of portfolio
Filing
OrbiMed Advisors
2,139,882
+2,139,882
0.07%
2026-08-14
Ikarian Capital
1,278,408
no change
0.36%
2026-08-14
ADAR1 Capital Management
210,000
+176,900
0.02%
2026-08-14
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.